Aetna Classifies PFAS Testing as Experimental Under CPB 1067 — What Billing Teams Need to Know

Aetna, a CVS Health company, has modified Clinical Policy Bulletin 1067 (CPB 1067), formally classifying laboratory testing for per- and polyfluoroalkyl substances (PFAS) — commonly called "forever chemicals" — as experimental, investigational, or unproven. Effective March 13, 2026, this policy update has direct billing consequences for any practice or lab submitting PFAS toxicology claims to Aetna members. If your revenue cycle touches occupational medicine, environmental toxicology, or general internal medicine, you need to understand what this policy says before claims start denying.

What Aetna's CPB 1067 Says About PFAS Testing Coverage

Aetna's position is unambiguous: all laboratory testing for PFAS — whether blood, urine, or other specimen types — is considered experimental, investigational, or unproven for the clinical evaluation and management of PFAS exposure or toxicity. The policy specifically names PFOA (perfluorooctanoic acid), PFOS (perfluorooctane sulfonate), and commercial panels marketed as "Forever Chemicals" panels as falling under this designation.

The rationale Aetna applies is that the clinical effectiveness of PFAS testing to guide patient management has not been established to the payer's evidence standard. This is a meaningful distinction — it's not that Aetna disputes PFAS are harmful, but that the payer sees insufficient evidence that ordering and acting on a blood or urine PFAS level changes clinical outcomes in a way that justifies coverage.

This is the kind of policy classification that creates immediate claim denial exposure. "Experimental or investigational" designations in payer policy bulletins typically mean no medical necessity argument alone will overcome the denial — you'd need a formal appeals process or, in some cases, a clinical trial enrollment exception.

Affected Codes Under Aetna CPB 1067

All five CPT codes listed in this policy fall into the non-covered category. There are no covered-with-criteria codes in this bulletin.

Not Covered / Experimental Codes

Codes 0394U, 0457U, 0535U, and 0589U are Proprietary Laboratory Analyses (PLA) codes — lab-specific codes assigned to branded PFAS panels. The inclusion of 82542 is notable because that code covers general column chromatography with mass spectrometry, a broader analytical method used across many test types. When PFAS is the indication, Aetna's policy pulls 82542 into non-covered territory as well.

Related ICD-10 Diagnosis Codes Referenced in CPB 1067

The following diagnosis codes are listed in the policy in the context of PFAS evaluation and management — and they are specifically associated with the non-covered services listed above. Appending these to any of the CPT codes above will not rescue a claim from denial under this policy.

The breadth of Z77.xx codes in this policy reflects how wide the potential exposure population is — workers in contaminated environments, residents near PFAS-producing facilities, and patients self-reporting chemical exposure all map into this range. Despite that clinical reality, the diagnosis codes alone don't create a coverage pathway under this policy.

Why This Policy Matters Beyond the Denial Rate

PFAS testing has grown significantly in the wake of EPA drinking water regulations and expanded public awareness of contaminated water supplies near military bases and industrial sites. Occupational medicine practices and primary care physicians serving affected communities have begun ordering PFAS panels with increasing frequency — often at patient request or following public health guidance.

The problem is that clinical demand and payer coverage are running on separate tracks. While the National Academies of Sciences, Engineering, and Medicine issued a 2022 report recommending PFAS blood level testing for exposed populations, Aetna's policy reflects a stricter evidentiary standard — specifically, that testing must demonstrably change clinical management. Until that evidence base matures, claims to Aetna will be denied regardless of how well-documented the exposure history is.

For labs offering high-complexity PFAS panels — particularly those billed under the 0394U–0589U PLA code range — this policy update means those panels have no reimbursement pathway through Aetna. That has financial modeling implications for any lab that built revenue projections around PFAS panel volume.

What Your Billing Team Should Do